Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms
Condition(s):Myeloproliferative Disorder; Aquagenic PruritusLast Updated:June 11, 2021Unknown status
Hide Studies Not Open or Pending
Condition(s):Myeloproliferative Disorder; Aquagenic PruritusLast Updated:June 11, 2021Unknown status
Condition(s):LeukemiaLast Updated:April 2, 2010Completed
Condition(s):Aplastic Anemia; Leukemia; Myelodysplastic SyndromeLast Updated:July 10, 2018Completed
Condition(s):Kidney CancerLast Updated:August 12, 2013Unknown status
Condition(s):Myeloproliferative Neoplasm (MPN); Essential Thrombocythemia (ET); JAK2 Mutation; Polycythemia Vera (PV); Primary Myelofibrosis; Venous Thromboembolism (VTE)Last Updated:August 1, 2023Active, not recruiting
Condition(s):Colorectal CancerLast Updated:July 19, 2023Withdrawn
Condition(s):HIV InfectionsLast Updated:October 29, 2021Completed
Condition(s):Carcinomatosis, PeritonealLast Updated:February 1, 2024Completed
Condition(s):Kidney CancerLast Updated:March 21, 2016Terminated
Condition(s):Kidney CancerLast Updated:January 10, 2014Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.